Literature DB >> 11475013

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.

M Hartbauer1, B Hutter-Paier, G Skofitsch, M Windisch.   

Abstract

Cerebrolysin (EBEWE Arzneimittel, Austria, Europe) is a widely used drug relieving the symptoms of a variety of neurological disorders, particularly of neurodegenerative dementia of the Alzheimer's type. It consists of approximately 25% of low molecular weight peptides (<10k DA) and a mixture of approximately 75% free amino acids, this being based on the total nitrogen content. In this study we used a low serum (2% serum supplement) cell stress in-vitro model to assess drug effectiveness on neuronal viability and programmed cell death (PCD). In this in-vitro model the type of cell death was previously shown to be primarly apoptotic, which was verified by DNA-laddering and TUNEL-staining. For evaluation of neuronal viability a MTT-reduction assay was performed after 4 DIV and 8 DIV and the percentage of apoptotic neurons was determined by bis-benzimide staining of nuclear chromatin. To differentiate between possible effects of the free amino acids and the peptide fraction of Cerebrolysin an artificial amino acid mixture (AA-mix) was used as a control. Cerebrolysin, the AA-mix and 10% foetal calf serum (FCS) caused a similar increase in viability after 4 DIV, whereas the effects of the growth factors BDNF and FGF-2 were less pronounced. After 8 DIV Cerebrolysin, but not the AA-mix, was able to ameliorate neuronal viability, which could reflect a neuro-protective effect or an increased activity of the mitochondrial dehydrogenase measured in a MTT-reduction assay. The percentage of cells showing apoptotic chromatin changes was significantly reduced (p < 0.01) in cultures treated with Cerebrolysin, whereas the AA-mix failed to decrease the percentage of cells showing apoptotic chromatin changes. These findings ascertain an anti-apoptotic effect of the peptide fraction of Cerebrolysin and reveal a transient viability promoting effect of the amino acid fraction, which is most likely due to improved nutritional supply.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11475013     DOI: 10.1007/s007020170067

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  16 in total

1.  N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.

Authors:  M Windisch; B Hutter-Paier; E Grygar; E Doppler; H Moessler
Journal:  J Neural Transm (Vienna)       Date:  2005-03-07       Impact factor: 3.575

2.  Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.

Authors:  E Schauer; R Wronski; J Patockova; H Moessler; E Doppler; B Hutter-Paier; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

3.  Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients.

Authors:  Patrizia Formichi; Elena Radi; Carla Battisti; Giuseppe Di Maio; Maria Teresa Dotti; Dafin Muresanu; Antonio Federico
Journal:  Neurol Sci       Date:  2012-08-10       Impact factor: 3.307

Review 4.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

5.  PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury.

Authors:  Barbara Ruozi; Daniela Belletti; Hari S Sharma; Aruna Sharma; Dafin F Muresanu; Herbert Mössler; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Mol Neurobiol       Date:  2015-10       Impact factor: 5.590

6.  Spotlight on cerebrolysin in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 7.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

9.  Cerebrolysin administration reduces oxidative stress-induced apoptosis in lymphocytes from healthy individuals.

Authors:  Patrizia Formichi; Elena Radi; Carla Battisti; Giuseppe Di Maio; Dafin Muresanu; Antonio Federico
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

10.  Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Authors:  Dafin F Muresanu; Wolf-Dieter Heiss; Volker Hoemberg; Ovidiu Bajenaru; Cristian Dinu Popescu; Johannes C Vester; Volker W Rahlfs; Edith Doppler; Dieter Meier; Herbert Moessler; Alla Guekht
Journal:  Stroke       Date:  2015-11-12       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.